ROCK phosphorylates the oncogene c-Myc at T58 and/or S62, ensuring higher stability and transcriptional activity of c-Myc in breast cancer (Liu et al. 2009) and in prostate cancer (Zhang et al. 2014); hence the inhibition of ROCK lowers c-Myc activity. This evidence concerns the gene MYC and Familial prostate cancer.